Andrew Garza, PA
Medical · Dallas, TXNPI 1104561281
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Insulet Corporation at 40.5% of the total. 2025 is the largest year on record at $29,577, more than ten times the $1,895 reported in 2022. Among medical clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 919 payments — averaging $46.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$17K
- Medtronic$9K
- Abbott$3K
- Amgen$2K
- Corcept Therapeutics$2K
- Lilly USA, LLC$2K
- plus $8K from 36 others
Across 8 payments — averaging $267.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$2K
What the payments were for
- Consulting fees$4251%
- Speaking & faculty fees$21,41550%
- Travel & lodging$3,3788%
- Food & beverage$17,41940%
- Education$3551%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$16,504
- MINIMED 780G$6,744
- FreeStyle Libre$1,581
- Korlym$889
- FREESTYLE LIBRE 3$460
- iLet Bionic Pancreas$318
- MINIMED 770G$163
- TEPEZZA$154
- TWIIST$141
- CeQur Simplicity$123
- RYBELSUS$121
- EVENITY$117
- AFREZZA$114
- iLet Insulin Infusion Kit Inset$106
- iLet Insulin Infusion Kit Contact Detach$106
- Ozempic$105
How this compares
$43,053 in reported general payments places this provider in the 95th percentile of 1,490 medical providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 335 | $419,454 |
| JardianceEmpagliflozin | 236 | $228,837 |
| MounjaroTirzepatide | 130 | $166,108 |
| Tresiba Flextouch U-200Insulin Degludec | 108 | $143,345 |
| TrulicityDulaglutide | 51 | $79,779 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 67 | $64,008 |
| FarxigaDapagliflozin Propanediol | 83 | $60,031 |
| Teriparatide | 16 | $58,551 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $40,193 |
| VascepaIcosapent Ethyl | 81 | $39,790 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 36 | $38,982 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $38,525 |
| Humalog Kwikpen U-200Insulin Lispro | 22 | $35,693 |
| Repatha SureclickEvolocumab | 51 | $34,818 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 42 | $33,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,022 | $450,420380 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta | $245 | $319,861342 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $1,617 | $256,286212 claims |
| AstraZenecaFarxiga | $123 | $60,03183 claims |
| Alvogen IncTeriparatide | $48 | $58,55116 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $317 | $25,57426 claims |
| Esperion Therapeutics, Inc.Nexletol, Nexlizet | $150 | $12,52330 claims |
| Astellas Pharma US IncVeozah | $235 | $7,54214 claims |
| AbbVieSynthroid | $238 | $5,69962 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,490 medical providers in Texas.
Other medical in Dallas
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
- Alyssa SpiegelDallas$18K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Shakira CabreraSan Antonio$116K
- Courtney AldridgeSan Antonio$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.